CELL INTELLIGENCE · 肿瘤细胞治疗研究

诊断时 CD70 过表达预测滤泡性淋巴瘤复发并支持 CD19-CD70 双靶点 CAR-T 治疗

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

寻找 AML 中安全有效的 CAR-T 靶点

The search for safe and effective CAR-T targets in AML.

CAR-T 与 CAR NK 细胞治疗急性髓系白血病的最新进展

Recent advances in CAR T and CAR NK cell therapy for AML.

通过人 iNKT-DC 偶联物介导的 CD8+ T 细胞抗肿瘤免疫

CD8+ T-cell Antitumor Immunity via Human iNKT-DC Conjugates.

单细胞与 bulk 转录组学揭示预测弥漫大 B 细胞淋巴瘤预后的 CD8⁺ T 细胞基因特征

Single-cell and bulk transcriptomics reveal a CD8(+) T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma.

本研究突出了 DLBCL 中 CD8+ T 细胞的异质性，并建立了一个预后基因特征，可为患者生存预测和 CAR-T 治疗疗效提供信息。

急性髓系白血病 CAR-T 细胞治疗的新兴策略：通过双抗原靶向克服异质性并提高安全性

Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.

高危 MCL：识别与治疗

High-risk MCL: recognition and treatment.

CD70 是弥漫大 B 细胞淋巴瘤的潜在预后标志物并显著调控细胞功能

CD70 is a potential prognostic marker and significantly regulates cellular function in diffuse large B-cell lymphoma.

整合多组学分析揭示 ZZZ3/CD70 轴是弥漫大 B 细胞淋巴瘤细胞-NK 细胞相互作用的超级增强子驱动调控因子

Integrated multi-omics profiling reveals the ZZZ3/CD70 axis is a super-enhancer-driven regulator of diffuse large B-cell lymphoma cell-natural killer

敲除 CD70 使 CD70 特异性 NanoCAR T 细胞免于抗原诱导的耗竭

Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion.